Literature DB >> 16957822

A brief overview of acute respiratory distress syndrome.

Robert M Hardaway1.   

Abstract

BACKGROUND: The low pO: (2) in traumatic and septic shock was first documented at Walter Reed Army Medical Center starting in 1960. It was postulated that this respiratory failure was due to the occlusion of the pulmonary microcirculation by the microclots of disseminated intravascular coagulation (DIC).
MATERIALS AND METHODS: Animal studies showed that pulmonary failure and death could be caused by intravenous injection of a killed culture of either Escherichia coli or pneumococcal organisms or by severe muscle contusion. Severe clinical septic and traumatic shock cases were studied.
RESULTS: Injection of either killed E. coli or killed pneumococci resulted in acute respiratory distress syndrome (ARDS) and death in pigs. Muscle contusion also resulted in ARDS and death in pigs. Both ARDS and death were prevented by administration of a plasminogen activator, and ARDS in human septic or traumatic shock were safely and effectively treated by administration of a plasminogen activator.
CONCLUSIONS: Acute respiratory distress syndrome can be caused by DIC, which blocks the microcirculation of any and all organs. These microclots can be safely lysed by a plasminogen activator, thus treating ARDS and saving lives.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957822     DOI: 10.1007/s00268-006-0030-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  34 in total

Review 1.  Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock.

Authors:  R A Balk
Journal:  Crit Care Clin       Date:  2000-04       Impact factor: 3.598

2.  Mechanism of action of fibrinolysin in the prevention of irreversible hemorrhagic shock.

Authors:  R M HARDAWAY; J W BURNS
Journal:  Ann Surg       Date:  1963-02       Impact factor: 12.969

Review 3.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment.

Authors:  F Zeni; B Freeman; C Natanson
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

4.  Strategies for the treatment of sepsis.

Authors:  H S Warren
Journal:  N Engl J Med       Date:  1997-03-27       Impact factor: 91.245

5.  Continuous positive-pressure breathing (CPPB) in adult respiratory distress syndrome.

Authors:  D G Ashbaugh; T L Petty; D B Bigelow; T M Harris
Journal:  J Thorac Cardiovasc Surg       Date:  1969-01       Impact factor: 5.209

6.  Inapparent hypoxemia in casualties with wounded limbs: pulmonary fat embolism?

Authors:  J A Collins; W C Gordon; T L Hudson; R W Irvin; T Kelly; R M Hardaway
Journal:  Ann Surg       Date:  1968-04       Impact factor: 12.969

7.  Respiratory insufficiency in combat casualties. II. Pulmonary edema following head injury.

Authors:  R L Simmons; A M Martin; C A Heisterkamp; T B Ducker
Journal:  Ann Surg       Date:  1969-07       Impact factor: 12.969

8.  Systemic activation of tissue-factor dependent coagulation pathway in evolving acute respiratory distress syndrome in patients with trauma and sepsis.

Authors:  S Gando; S Nanzaki; Y Morimoto; S Kobayashi; O Kemmotsu
Journal:  J Trauma       Date:  1999-10

Review 9.  Traumatic and septic shock alias post-trauma critical illness.

Authors:  R M Hardaway
Journal:  Br J Surg       Date:  1998-11       Impact factor: 6.939

10.  Erythrocyte membrane lipid reorganization during the sickling process.

Authors:  D Chiu; B Lubin; S B Shohet
Journal:  Br J Haematol       Date:  1979-02       Impact factor: 6.998

View more
  11 in total

1.  The effect of aerosolized indomethacin on lung inflammation and injury in a rat model of blunt chest trauma

Authors:  Raymond L. Kao; Weixiong Huang; Claudio M. Martin; Tao Rui
Journal:  Can J Surg       Date:  2018-12-01       Impact factor: 2.089

2.  Isoflurane prevents acute lung injury through ADP-mediated platelet inhibition.

Authors:  Jeffrey N Harr; Ernest E Moore; John Stringham; Max V Wohlauer; Miguel Fragoso; Wilbert L Jones; Fabia Gamboni; Christopher C Silliman; Anirban Banerjee
Journal:  Surgery       Date:  2012-08       Impact factor: 3.982

3.  Activated platelets in heparinized shed blood: the "second hit" of acute lung injury in trauma/hemorrhagic shock models.

Authors:  Jeffrey N Harr; Ernest E Moore; Max V Wohlauer; Miguel Fragoso; Fabia Gamboni; Xiayuan Liang; Anirban Banerjee; Christopher C Silliman
Journal:  Shock       Date:  2011-12       Impact factor: 3.454

4.  Treatment with Fms-like tyrosine kinase 3 ligand reverses lung dendritic cell immunoparalysis and ameliorates zymosan-induced secondary lung injury in mice.

Authors:  H W Wang; W Yang; J Y Lu; G Tian; F Li; X H Wang; J R Kang; Y Yang
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

5.  N-acetylcysteine administration is associated with reduced activation of NF-kB and preserves lung dendritic cells function in a zymosan-induced generalized inflammation model.

Authors:  Hong-Wei Wang; Wen Yang; Jiang-Yang Lu; Fei Li; Jun-Zhong Sun; Wen Zhang; Nan-Nan Guo; Lei Gao; Jia-Rui Kang
Journal:  J Clin Immunol       Date:  2012-12-16       Impact factor: 8.317

6.  Antiplatelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients.

Authors:  Jeffrey N Harr; Ernest E Moore; Jeffrey Johnson; Theresa L Chin; Max V Wohlauer; Ronald Maier; Joseph Cuschieri; Jason Sperry; Anirban Banerjee; Christopher C Silliman; Angela Sauaia
Journal:  Crit Care Med       Date:  2013-02       Impact factor: 7.598

7.  Shock - A reappraisal: The holistic approach.

Authors:  Fabrizio Giuseppe Bonanno
Journal:  J Emerg Trauma Shock       Date:  2012-04

Review 8.  Thrombosis and Haemostasis challenges in COVID-19 - Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review.

Authors:  Laura Mazilu; Niki Katsiki; Taxiarchis Konstantinos Nikolouzakis; Minas I Aslanidis; George Lazopoulos; Dimitrios Kouretas; Aristidis Tsatsakis; Andra-Iulia Suceveanu; Anca-Pantea Stoian; Irinel-Raluca Parepa; Felix Voinea; Adrian Paul Suceveanu; Andreea Letiția Arsene; Bruno Ștefan Velescu; Cosmin Vesa; Cornelia Nitipir
Journal:  Food Chem Toxicol       Date:  2021-01-06       Impact factor: 5.572

Review 9.  Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.

Authors:  Claire S Whyte; Gael B Morrow; Joanne L Mitchell; Pratima Chowdary; Nicola J Mutch
Journal:  J Thromb Haemost       Date:  2020-06-03       Impact factor: 16.036

10.  Telmisartan mitigates lipopolysaccharide (LPS)-induced production of mucin 5AC (MUC5AC) through increasing suppressor of cytokine signaling 1 (SOCS1).

Authors:  Ling Chen; Jiajia Xu; Meiyu Deng; Yanling Liang; Jinfu Ma; Linghui Zhang; Yijie Wang; Jinping Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.